Back

Diagnostic and prognostic value of the gasdermins in gastric cancer

xu, y.; Wan, C.; wang, p.; Gu, Y.

2023-10-24 genetic and genomic medicine
10.1101/2023.10.18.23297225
Show abstract

BackgroundPyroptosis has been drawn attention owing to its contributory role in various cancers. Recently, the participator of pyroptosis, gasdermins (GSDMs) have been reported associated with of multiple types of cancers. However, the role of GSDMs expression in diagnosis and prognosis of gastric cancer (GC) has not been well elucidated. Moreover, the mechanisms underlying the carcinogenesis of GC are still obscure. MethodsHerein we analyzed the transcriptional, prognostic information and the role of GSDMs in patients with GC from TIMER, UALCAN, Human Protein Atlas (HPA), GEPIA and Kaplan-Meier plotter databases. The cBioPortal online tool was used to analyze the GSDMs alterations, correlations, and networks. Furthermore, String, Cytoscape and TIMER were conducted to explore the functional enrichment and immune modulation. The statistical analysis was carried out in the R environment, and P-value < 0.05 was considered statistically significant. ResultsGSDMB, GSDMC, GSDMD, GSDME were with higher expression in GC than normal tissue in TIMER database. Moreover, survival analyses via two databases both demonstrated that high expression of GSDME was related to shorter overall survival (OS) in patients with GC. Additionally, functional enrichment revealed that GSDMs might be involved in endopeptidase activity, peptidase regulator activity, cysteine-type peptidase activity. Besides, GSDMs were correlated with infiltration levels of immune cells in GC, and GSDME was correlated with the infiltrating level of CD4+ T, CD8+ T, neutrophils, macrophages and dendritic cells. ConclusionsThe study systematically indicated the potential diagnostic and prognostic value of GSDMs in GC. Our results showed that GSDME might play a considerably oncogenic role in GC diagnosis and prognosis. However, our bioinformatics analyses should be further validated in more prospective studies.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
Cancers
based on 57 papers
Top 0.6%
15.8%
2
Scientific Reports
based on 701 papers
Top 41%
4.6%
3
Frontiers in Genetics
based on 32 papers
Top 0.5%
4.6%
4
Frontiers in Oncology
based on 34 papers
Top 2%
4.6%
5
eLife
based on 262 papers
Top 5%
4.6%
6
International Journal of Molecular Sciences
based on 39 papers
Top 0.3%
4.6%
7
Genomics, Proteomics & Bioinformatics
based on 10 papers
Top 0.4%
3.0%
8
Aging
based on 18 papers
Top 0.7%
2.9%
9
BMC Medical Genomics
based on 12 papers
Top 0.1%
2.9%
10
PLOS ONE
based on 1737 papers
Top 83%
2.5%
50% of probability mass above
11
Genome Medicine
based on 56 papers
Top 4%
2.4%
12
Journal of Translational Medicine
based on 21 papers
Top 0.3%
2.3%
13
Journal of Medical Virology
based on 95 papers
Top 6%
1.6%
14
iScience
based on 74 papers
Top 3%
1.6%
15
JNCI: Journal of the National Cancer Institute
based on 13 papers
Top 1%
1.4%
16
Frontiers in Immunology
based on 140 papers
Top 5%
1.4%
17
Frontiers in Molecular Biosciences
based on 10 papers
Top 0.3%
1.4%
18
Biomedicines
based on 21 papers
Top 2%
1.4%
19
Nature Communications
based on 483 papers
Top 34%
1.4%
20
Human Genomics
based on 13 papers
Top 1%
1.2%
21
Clinical and Translational Medicine
based on 11 papers
Top 1%
1.2%
22
Genetics in Medicine
based on 57 papers
Top 4%
1.2%
23
British Journal of Cancer
based on 22 papers
Top 3%
1.2%
24
Frontiers in Pharmacology
based on 27 papers
Top 4%
0.8%
25
Computational and Structural Biotechnology Journal
based on 14 papers
Top 2%
0.8%
26
Briefings in Bioinformatics
based on 11 papers
Top 0.6%
0.8%
27
Cells
based on 14 papers
Top 1%
0.8%
28
Human Mutation
based on 14 papers
Top 2%
0.8%
29
Signal Transduction and Targeted Therapy
based on 10 papers
Top 1%
0.7%
30
Journal of Medical Genetics
based on 22 papers
Top 2%
0.7%